Lake Street initiates Oncology Institute stock coverage with buy rating By Investing.com
Lake Street has initiated coverage on The Oncology Institute Inc. (NASDAQ:TOI) with a Buy rating and a $10.00 price target, citing significant growth in oncology drug spending. The company recently exceeded Q1 2026 earnings expectations, and another firm, Needham, also raised its price target for TOI to $7.00. These positive developments highlight the company's strong performance and future prospects in the oncology market.
IQVIA stock steadies on a thin catalyst day.
IQVIA Holdings' stock remained steady despite a thin catalyst day, focusing on its core clinical research and healthcare analytics business. The article highlights the company's Nasdaq listing, recurring demand profile, and its role as a large-cap healthcare services provider to pharmaceutical and life-science customers. Its business model combines contract research services with technology-enabled analytics, relying on data, software, and outsourced trial execution.
IQVIA stock holds focus on its data and services model.
IQVIA Holdings (IQV) is highlighted as a large-cap healthcare services company, specializing in clinical research, analytics, and technology for life sciences clients. The company's business model relies on recurring data and technology work combined with outsourcing demand from drug developers and pharmaceutical groups. For investors, the key considerations are the durability of spending in clinical development and real-world evidence, along with the company's margin discipline and execution across its global customer base.
The IQVIA CORE – IQVIA Holdings leans on real-world data backbone
IQVIA CORE serves as the integrated engine combining data, advanced analytics, technology, and domain expertise into a unified backbone for life-science customers globally. It ingests massive amounts of clinical, claims, and consumer data, driving IQVIA's solutions for commercial analytics, market measurement, and real-world evidence. For U.S. pharmaceutical and biotech companies, CORE offers predictability and comprehensive data for R&D and commercial intelligence, functioning as a structural moat for IQVIA Holdings.
MEDP - Medpace Holdings Inc Latest SEC Filings
This article provides the latest SEC filings information for Medpace Holdings Inc (MEDP), along with comprehensive financial data, key performance indicators, and company statistics. It details various financial ratios, insider and institutional ownership, profitability margins, and stock performance metrics for the company.
IQVIA Holdings outlines its data-driven healthcare model as a long-term growth story
IQVIA Holdings provides advanced analytics, technology solutions, and clinical research services to the life sciences industry, integrating contract research with real-world data and software. The company focuses on using data science and technology to improve drug development efficiency, market access, and commercial performance for pharmaceutical, biotechnology, and medical device firms. Its model helps clients understand therapies' real-world performance, design clinical trials, and manage sales and marketing activities.
CRL - Charles River Laboratories International Inc Latest SEC Filings
This article provides a detailed financial overview and recent SEC filing information for Charles River Laboratories International Inc (CRL). It covers key financial metrics, stock performance data, analyst ratings, and details on insider and institutional ownership, offering a comprehensive snapshot of the company's current market position.
IQVIA Holdings Inc outlook and operations as a healthcare data leader
IQVIA Holdings Inc. is highlighted as a leading provider of healthcare analytics, technology solutions, and clinical research services globally, emphasizing its role in supporting the life-sciences industry with data-driven services. The company combines extensive healthcare data with software and services for drug development, commercialization, and real-world evidence generation. Its focus on technology and analytics helps streamline clinical trials, monitor safety, evaluate outcomes, and support value-based care.
IQVIA Holdings (IQV) Is Up 11.1% After Raising Earnings Outlook And Highlighting AI Research Role
IQVIA Holdings (IQV) saw an 11.1% stock increase after raising its adjusted earnings guidance and reaffirming revenue expectations, reinforced by positive analyst commentary. The company highlighted its crucial role in AI-enabled clinical research, particularly with its IQVIA.ai platform developed with NVIDIA, framing AI tools as a potential offset to cost pressures. While AI excitement is present, investors are reminded to consider IQVIA's elevated leverage and diverse perspectives on its future valuation.
Here's Why Investors Should Hold IQV Stock in Their Portfolios Now
The article recommends holding IQVIA (IQV) stock, citing its recent strong share performance, positive revenue and EPS growth expectations for 2026 and 2027, and its robust AI capabilities and significant R&D backlog. While highlighting a shareholder-friendly strategy and strong earnings quality, it also points out risks such as past industry turbulence, lack of dividends, and weak liquidity, advising investors to weigh these factors.
NTRA - Natera Inc Options
This article provides a detailed financial overview of Natera Inc. (NTRA), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's valuation ratios, growth rates, and market indicators as of July 2, 2024.
IQVIA Symphony Health Integrated Dataverse - Subscription data that shapes US drug launches
IQVIA Symphony Health Integrated Dataverse is a subscription service offering longitudinal prescription and medical claims data across the US market, designed for pharmaceutical and biotech firms. It provides de-identified patient-level data for commercial teams to analyze drug launches, patient journeys, and market access strategies. This service is a key component of IQVIA's recurring revenue in its Commercial segment, supporting various use cases from launch planning to managing loss of exclusivity.
IQVIA Holdings Inc (IQV) Stock Price, Quote, News & History
This page provides comprehensive information on IQVIA Holdings Inc. (IQV), including its current stock price, key financial metrics, recent news, analyst ratings, and company overview. IQV closed at $207.04 on July 2, 2026, with a market cap of $34.55 billion and a P/E ratio of 25.24. The company, a global leader in clinical research and technology solutions for the life science industry, has a consensus price target of $235.92 from analysts.
IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains
IQVIA Holdings Inc. (IQV) stock rose by 1.89% on Thursday, closing at $207.04. Despite these daily gains, the stock underperformed compared to its competitors, even as the Dow Jones Industrial Average saw a significant increase. This marks the second consecutive day of gains for IQVIA Holdings Inc.
Hardman Johnston Large Cap Equity Holds Firm on IQVIA Holdings (IQV). Here’s Why
Hardman Johnston Large Cap Equity Strategy maintained its position on IQVIA Holdings Inc. (IQV) in Q1 2026, despite the stock being under pressure from AI disruption fears and rising interest rates. The firm believes IQVIA's capabilities make it a strong player in the biotech and pharmaceutical industries. Although IQVIA is not among the most popular stocks with hedge funds, other investors like Artisan Value Fund have also initiated positions, highlighting the company's proprietary data and domain expertise.
Hardman Johnston Large Cap Equity Holds Firm on IQVIA Holdings (IQV). Here’s Why
Hardman Johnston Large Cap Equity Strategy reported a 0.68% gross return in Q1 2026, outperforming the S&P 500's -4.33% decline. The firm highlighted IQVIA Holdings Inc. (IQV) as a key holding, despite pressures from AI disruption fears and rising interest rates impacting smaller customers. Hardman Johnston believes IQVIA's capabilities make it a strong player, emphasizing that the overall U.S. economy outlook remains positive.
IQVIA Holdings stock. Identity holds, catalyst stays general
The article confirms that IQVIA Holdings (US46266C1053) maintains its identity and New York Stock Exchange listing. As a large healthcare data and contract research group, its revenue is tied to pharmaceutical development and analytics, providing recurring exposure to sponsor budgets. There are no fresh catalysts or live stock quotes available in the current search, so the analysis remains at a general company and market level.
IDXX - Idexx Laboratories Inc Volatility & Greeks
This article provides a detailed financial overview of Idexx Laboratories Inc. (IDXX), including its current stock performance, key financial metrics, volatility indicators, and analyst recommendations. It covers various data points from market capitalization to insider transactions and performance across different timeframes, offering a comprehensive snapshot of the company's financial health and stock behavior.
DGX - Quest Diagnostics Inc Options
This article provides a comprehensive financial overview of Quest Diagnostics Inc. (DGX), including its market performance, valuation metrics, dividend information, and growth rates. Key financial data points such as P/E ratio, market capitalization, sales, and various performance indicators are detailed.
IQVIA Holdings Inc (IQV) Stock Up 5.2% and Still Undervalued -- GF Score: 90/100
IQVIA Holdings Inc (IQV) saw its stock rise by 5.2% to $203.20, yet it remains undervalued according to GuruFocus's GF Value™ at $249.26. The company boasts a strong GF Score™ of 90/100, driven by excellent profitability and growth, despite having a weaker financial strength score. The stock's current P/E ratio is also below its historical median, reinforcing its undervalued status.
Baird Maintains IQVIA Holdings(IQV.US) With Buy Rating, Cuts Target Price to $249
Baird has reiterated its Buy rating on IQVIA Holdings (IQV.US) but has lowered its target price for the stock to $249. This indicates continued confidence in the company's prospects despite a revised valuation.
IQVIA Holdings Inc. stock outperforms competitors on strong trading day
IQVIA Holdings Inc. (IQV) stock advanced 5.17% to $203.20 on Wednesday, outperforming broader market indices like the S&P 500 and Dow Jones Industrial Average, which saw declines. The company's shares closed 17.75% below their 52-week high.
IQV - IQVIA Holdings Inc Volatility & Greeks
This article provides a detailed financial overview of IQVIA Holdings Inc (IQV), including its stock performance, key financial metrics, volatility data, and institutional ownership. It highlights the company's recent stock price change, market capitalization, earnings per share, and various ratios, offering a comprehensive snapshot for investors.
IQV - IQVIA Holdings Inc Latest SEC Filings
This article provides the latest SEC filing information for IQVIA Holdings Inc. (IQV), including its stock performance, key financial metrics, insider ownership, institutional ownership, and various valuation ratios. The data covers market capitalization, sales, earnings per share, profit margins, and performance over different timeframes.
IQVIA Holdings Inc. stock rises Monday, still underperforms market
IQVIA Holdings Inc. (IQV) stock increased by 1.12% on Monday, closing at $193.28. Despite this gain, the stock underperformed the broader market, as the S&P 500 Index rose by 1.18% and the Dow Jones Industrial Average gained 0.59%. This marks the sixth consecutive day of gains for IQVIA Holdings Inc.
Charles River Laboratories strategy focus, S&P 500 health stock in contract research
Charles River Laboratories is a key US health-sector contract research provider listed on the NYSE and part of the S&P 500 index. The company specializes in preclinical and clinical contract research services, helping pharmaceutical and biotech firms outsource essential development steps, particularly in early-stage research and animal models for drug development. Its strategy focuses on being a full-service partner, leveraging structural outsourcing trends to achieve scale efficiencies and maintain strong client relationships.
The Orchestrated Patient Recruitment from IQVIA Holdings Inc. - data-driven outreach for tough trial
IQVIA Holdings Inc. offers an "Orchestrated Patient Recruitment" program that leverages real-world data, analytics, and multi-channel outreach to accelerate clinical trial enrollment, particularly for complex studies. This service aims to improve recruitment timelines, retention rates, and lower screen-failure rates by pre-filtering eligible patients. It integrates with IQVIA's broader services, providing an end-to-end solution for biopharma sponsors and contract research organizations.
IQVIA Holdings Inc Actuals & Estimates (NYSE:IQV)
This article provides financial actuals and estimates for IQVIA Holdings Inc. (NYSE:IQV), including its current stock price, historical performance, analyst forecasts, and upcoming earnings dates. It highlights that IQV's stock has risen recently, analysts have a positive outlook with a maximum estimate of $284.00, and the company is expected to release its next earnings report on July 28, 2026.
Labcorp focuses on long-term strategy, shares supported by healthcare demand
Labcorp is undergoing a multi-year transformation of its diagnostics and drug-development businesses, supported by steady healthcare demand and insurance spending. The company reported first-quarter 2026 revenue of approximately $3.2 billion, driven by strong testing volumes and central laboratory services for pharmaceutical trials, with a focus on high-growth areas like specialty diagnostics. Labcorp (LH) shares recently traded around $271 on the NYSE, with a market capitalization near $22 billion.
(IQV) as a Liquidity Pulse for Institutional Tactics
This article provides an institutional analysis of Iqvia Holdings Inc. (NYSE: IQV), highlighting divergent sentiment and a mid-channel oscillation pattern. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The report also includes a multi-timeframe signal analysis, showing varying signal strengths and support/resistance levels.
IQVIA Holdings consensus stays constructive, shares trade near record territory
IQVIA Holdings maintains a strong Wall Street consensus with analysts largely recommending "Buy," and shares are trading near their 52-week high. Analysts anticipate continued earnings growth, supported by the company's robust backlog, recurring data revenue, and its technology-enabled clinical services. The company's revenue generation from Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, combined with its real-world data and analytics platforms, positions it well for future growth.
Is IQVIA (IQV) Balancing Slower Revenue Momentum With Its Latest Debt Refinancing Move?
IQVIA Holdings is under scrutiny due to slower revenue growth and soft demand, compounded by a recent US$950 million debt refinancing. The company is attempting to balance shareholder returns with debt management, while analysts forecast varying revenue and earnings goals. Investors are advised to consider the company's elevated debt and ongoing refinancing needs against its projected fair value and growth catalysts.
QTS Forecast — Price Target — Prediction for 2027
This article provides key financial information and analyst forecasts for IQVIA Holdings Inc. (QTS). It includes a price target, analyst ratings, historical stock performance, and details on EPS, revenue, net income, and employee count. The stock does not pay dividends, but future earnings and revenue estimates are provided, along with instructions on how to trade the stock.
IQVIA Holdings Jumps 7.4% Amid Sector-Wide Rally
IQVIA Holdings Inc. (IQV) surged 7.4% to $184.00, driven by a sector-wide rally in the diagnostics and research industry. This strong performance, mirrored by several industry peers, suggests that investors are responding to broader positive trends affecting the sector rather than company-specific news. The company's market capitalization now stands at $30.7 billion, reinforcing its role as a key indicator for the contract research organization space.
Nanox Announces First Quarter 2026 Financial Results and Provides Business Updates
Nanox (NASDAQ: NNOX) announced its first quarter 2026 financial results, reporting $4.3 million in revenue, up from $2.8 million in Q1 2025. The medical imaging technology company is focusing on partnerships, strategic deployments, and improving its cost structure, with Nanox.ARC systems now in commercial use at locations like RadNet. Despite increased revenue, the company reported a net loss of $14.3 million for the quarter, and due to variable deployment timelines and revenue recognition, no longer expects to achieve its previously announced 2026 revenue target, stating it will instead focus on operational and commercial milestones.
Barclays Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $210
Barclays has reiterated its Buy rating on IQVIA Holdings (IQV.US), maintaining a target price of $210. This indicates a continued positive outlook from the firm regarding IQVIA's stock performance and value.
Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat to Buy
Abbott Laboratories (NYSE: ABT) is highlighted as an "unstoppable dividend aristocrat" with a strong business model, suitable for long-term ownership. The company boasts 54 consecutive years of dividend increases, a diversified four-segment healthcare engine, and recession-resistant markets, making it a reliable cash-compounding stock. Despite a recent market dip, its current price of $90.53 offers a discounted entry point compared to analyst targets, coupled with a meaningful yield and exposure to secular growth in chronic diseases.
IQVIA Holdings Inc. stock outperforms competitors on strong trading day
Shares of IQVIA Holdings Inc. (IQV) rose by 8.37% on Wednesday, closing at $185.62. This strong performance occurred during a mixed trading session where the Dow Jones Industrial Average gained, but the S&P 500 Index declined. This marks the third consecutive day of gains for IQVIA Holdings Inc. stock.
Welltower Inc stock hits all-time high at 221.75 USD
Welltower Inc. (WELL) stock hit an all-time high of $221.75, reflecting strong market performance with a 44.53% increase over the past year. Despite being considered overvalued by InvestingPro, the healthcare REIT has consistently paid dividends for 51 years. The company recently reported strong Q1 2026 earnings, surpassing analyst expectations, and Mizuho raised its price target, indicating continued strong financial performance and investor confidence.
Molecular Partners AG (MOLN) Earnings Forecast: Future EPS & Revenue Growth Estimates
Molecular Partners AG (MOLN) has an earnings forecast score of 8.00, placing it 166th in the Biotechnology & Medical Research industry. Analysts provide an average price target of $13.62, with a "Buy" consensus based on 5 analysts. The company's previous quarter EPS was -$0.42, beating the market expectation of -$0.44, and the next quarter's EPS is projected to be -$0.43.
HSBC Cuts PT on Danaher Corporation (DHR) – Here’s Why
HSBC recently cut its price target on Danaher Corporation (DHR) to $230 from $270 but maintained a Buy rating, citing bearish market expectations for life science tools despite "green shoots of recovery" in bioprocessing. Separately, Wolfe Research downgraded DHR to Peer Perform, noting its valuation compared to Thermo Fisher and confusion regarding its identity after the Masimo transaction. Danaher, a significant diagnostics stock, operates across various scientific and industrial sectors.
Does Slower Growth at IQVIA Holdings (IQV) Challenge Its Core Data‑Driven Pharma Enablement Story?
IQVIA Holdings is facing growth challenges, with revenue increases lagging peers and constant-currency trends indicating softer demand and market share pressure. This situation creates tension between IQVIA’s role in drug development and commercialization and its current struggle for stronger growth momentum. The company's recent move to raise US$950 million in new senior notes to refinance existing debt is particularly relevant, and its ability to manage refinancing, interest costs, and balance sheet flexibility will influence how investors perceive its trade-off between slower revenue growth, buybacks, and investments in AI and data platforms.
IQVIA Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains
Shares of IQVIA Holdings Inc. (IQV) rose by 2.07% on Tuesday, closing at $171.28. Despite this daily gain, the stock underperformed compared to its competitors as both the S&P 500 Index and the Dow Jones Industrial Average experienced declines. This marks the second consecutive day of gains for IQVIA Holdings Inc. amidst a generally grim trading session.
IQVIA Holdings Inc (IQV) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of IQVIA Holdings Inc (IQV), detailing its current price momentum score, support and resistance levels, and indicator and moving average signals. It notes that IQV's price momentum score is 6.76, suggesting suitability for range-bound swing trading between $156.15 and $185.08. The analysis concludes with a strong "Sell" signal based on the compiled technical indicators and moving averages.
IQVIA Holdings analyst views shift, shares trade below recent targets
IQVIA Holdings (US46266C1053) is experiencing mixed analyst views, with a recent downgrade from Morgan Stanley offset by reiterated Buy ratings from others like TD Cowen and Rothschild & Co Redburn. Despite the varied opinions, the stock trades around $168, significantly below the aggregated 12-month target price of approximately $284 from Wall Street analysts. The company primarily generates revenue from clinical research services and healthcare data analytics for various healthcare industry players.
How Is Charles River Laboratories’ Stock Performance Compared to Other Health Care Stocks?
Charles River Laboratories International, Inc. (CRL) is a mid-cap healthcare company providing non-clinical drug development services. While CRL's shares have outperformed the State Street Health Care Select Sector SPDR ETF (XLV) over the past three months, it has lagged XLV over the past 52 weeks and year-to-date. Analysts remain optimistic about CRL, with a "Strong Buy" consensus rating and a price target suggesting an 18.3% upside from current levels, boosted by a recent Morgan Stanley upgrade.
VolitionRX Ltd (VNRX) Earnings Forecast: Future EPS & Revenue Growth Estimates
VolitionRX Ltd (VNRX) currently holds an earnings forecast score of 7.50, ranking 289 out of 389 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $2.25 for VNRX, with a significant upside potential of +1086.43%. The company's expected revenue for the next quarter is $482.67K, and analysts generally recommend a "Buy" rating for its stock.
Fibrobiologics Inc (FBLG) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Fibrobiologics Inc (FBLG), including EPS and revenue growth estimates. Based on one analyst, the stock has a "Buy" rating with a target price indicating a significant upside. The previous quarter's EPS was better than market expectations, and the next quarter's EPS is also projected.
IQVIA Holdings - Analyst consensus and long-term drivers
IQVIA Holdings (IQV) maintains a positive analyst outlook due to its strong position in healthcare data and contract research. The article highlights the company's long-term growth drivers, including demand for real-world evidence and decentralized clinical trials, and notes an average analyst price target suggesting significant upside.
Why IQVIA’s Orchestrated Customer Engagement quietly shapes pharma sales
IQVIA's Orchestrated Customer Engagement (OCE) platform is a cloud-based CRM tailored for life sciences, built on Salesforce technology, that integrates sales, medical, and marketing interactions for pharmaceutical companies. It aims to streamline operations, enhance customer contact, and leverage IQVIA's extensive healthcare data and AI for precise targeting and compliance. While it offers significant benefits in coordination and data-driven insights, implementation can be complex and resource-intensive, particularly for large global organizations.
